Peptone, a London, UK -based the molecular computational physics company focused on protein drug discovery, announced the successful completion of a $40 million Series A financing.
The round was led by F-Prime Capital and Bessemer Venture Partners, with participation from Walden Catalyst Ventures and existing investors, including Hoxton Ventures and dRX Capital, the venture arm of Novartis.
Peptone series A round is use to develop the world’s most advanced facility dedicated to solving complex and problematic intrinsically disordered protein structures at scale, pioneering a new class of potential therapeutic targets and drugs.
Company: Peptone Ltd.
Round: Series A
Funding Month: June 2022
Lead Investors: F-Prime Capital and Bessemer Venture Partners
Additional Investors: Walden Catalyst Ventures, Hoxton Ventures, and dRX Capital
Company Website: https://peptone.io/
Software Category: Therapeutics Development platform
About the Company: Innovative drug discovery pioneers Peptone are applying advanced biophysics, atomic-level experimental approaches, cutting-edge supercomputing, and machine learning to the challenge of biopharmaceutical research and development. By bringing these proprietary approaches together, we are exploring the world of intrinsically disordered proteins (IDPs) – proteins without a fixed structure that play a significant role in health and disease – opening up the possibility of novel therapeutics against an entire class of the high value and previously undruggable targets. For further information about Peptone and the company’s technology.